Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal doxorubicin + paclitaxel + trastuzumab + pertuzumab
- Development stage
- Unknown
- Lead developer
- SOLTI
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The OptiHER-Heart regimen is a neoadjuvant combination therapy developed for the treatment of HER2-positive early breast cancer. It consists of four active components: non-pegylated liposomal doxorubicin (Myocet), paclitaxel, trastuzumab, and pertuzumab. Trastuzumab and pertuzumab are monoclonal antibodies that provide dual HER2 blockade by targeting different epitopes of the HER2 receptor. Paclitaxel is a taxane chemotherapy agent that stabilizes microtubules, while liposomal doxorubicin is an anthracycline that inhibits topoisomerase II and intercalates DNA. The regimen was specifically evaluated in the Phase II OptiHER-Heart trial (SOLTI-1002) by the SOLTI Breast Cancer Research Group to optimize pathological complete response rates while minimizing the cardiotoxicity typically associated with anthracycline-based treatments in HER2-positive patients.
- Brand names
- MyocetHerceptinPerjeta
- Other names
- OptiHER-Heart regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on liposomal doxorubicin + paclitaxel + trastuzumab + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal doxorubicin + paclitaxel + trastuzumab + pertuzumab.